Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
The purpose of this study is to explore the safety and activity of docetaxel + ASA404 as second-line chemotherapy in patients with advanced urothelial carcinoma.
Urothelial Carcinoma
DRUG: Docetaxel|DRUG: ASA404
To determine the best overall response rate (as measured by RECIST version 1.1) of docetaxel + ASA404 as second line therapy in patients with advanced urothelial carcinoma., 12 months
To evaluate progression-free survival in patients with advanced urothelial carcinoma, 12 months|To evaluate survival at 1 year from start of treatment in patients with advanced urothelial carcinoma treated with docetaxel + ASA404 as second line therapy, 12 months|To evaluate the safety of docetaxel and ASA404 combination, as measured by the NCI Common Toxicity Criteria version 3.0, 12 months
OUTLINE: This is a multi-center study.

21 Day Cycle Treatment Regimen:

* Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1
* ASA404 (given after Docetaxel) IV 1800 mg/m2 over approximately 20 minutes on Day 1

Treatment will continue until disease progression or intolerable treatment related adverse effects.

Karnofsky performance status of â‰¥ 70% within 7 days prior to registration for protocol therapy.

Life Expectancy: Not specified

Hematopoietic:

* Hemoglobin (Hgb) \> 9 g/dL
* Platelets \> 100 K/mm3
* Absolute neutrophil count (ANC) \> 1.5 K/mm3
* INR or Prothrombin Time (PT) \< 1.5 x ULN

Hepatic:

* Bilirubin \< 1.5 x ULN
* Aspartate aminotransferase (AST, ALT) \< 2.5 x ULN

Renal:

* Calculated creatinine clearance of \> 45 cc/min using the Cockcroft-Gault formula

Cardiovascular:

* No congestive heart failure (NY Heart Association class III or IV)
* No myocardial infarction within 12 months of study registration for protocol therapy or with implanted cardiac pacemaker
* No unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris